A-LIGN

Emergn is a global digital business services firm with a mission to improve the way people and companies work. Forever. Founded in 2009 and headquartered in London, the company combines in-depth consulting, product-focused capability development, and software engineering services to help enterprises achieve lasting competitive advantage. Unlike traditional consultancies that focus on temporary fixes, Emergn embeds a complete work operating system - the mindset, measures, and mechanics that govern how organizations decide what to build, how they build it, and how they measure success. The company operates across three interconnected areas: Process, People, and Technology. Emergn shapes how organizations turn ambitions into reality, helping them become faster, clearer, and more innovative than their competitors. Their methodology, VFQ (Value, Flow, Quality), combines the best of Agile, Lean, design thinking, and systems thinking to deliver tangible results. With offices in the US, UK, Ireland, Latvia, Portugal, Ukraine, and Romania, Emergn serves Fortune and FTSE companies across retail, energy, financial services, pharmaceuticals, and technology sectors. Their philosophy is grounded in the belief that the only sustainable competitive advantage is the way you work - and their goal is to set clients free by solving the root problems in how they operate, not just treating symptoms.

Genmab is an international biotechnology company that has been transforming cancer treatment for over two decades. Founded in 1999, Genmab has established itself as a leader in antibody therapeutics, with a proven track record of creating breakthrough medicines that improve patients' lives. The company has successfully developed multiple approved antibody therapeutics that are marketed globally, bringing innovative treatments to patients with cancer and other serious diseases. With headquarters in Denmark and offices across the Netherlands, United States, Japan, and the United Kingdom, Genmab operates as a truly global organization. The company's expertise spans the entire antibody development process, from discovery through commercialization, leveraging proprietary technology platforms to create differentiated therapeutics. Genmab's pipeline includes numerous investigational medicines in clinical development, reflecting the company's commitment to pushing the boundaries of antibody science to address unmet medical needs.

Ayvens manages 3.4 million vehicles across 42 countries, making it one of the world's largest fleet leasing and mobility companies. With more than 14,500 employees, Ayvens operates the biggest fleet of electric vehicles for multiple brands globally. The company was formed from the landmark merger of ALD Automotive and LeasePlan, two industry leaders, creating an undisputed leader in sustainable mobility. Committed to decarbonizing mobility, Ayvens provides full-service leasing, flexible subscription services, and comprehensive fleet management solutions for large international corporates, SMEs, and private individuals. The company manages over 600,000 electric vehicles and is leading the charge toward net-zero emissions. Ayvens delivers seamless digital experiences through its My Ayvens platform, while maintaining a strong focus on customer service, operational excellence, and sustainable value creation.

In 2015, OptiSigns emerged from a straightforward observation: digital signage was too complex, too expensive, and too technical for the businesses that needed it most. Small retailers, restaurants, and corporate offices struggled with clunky interfaces and proprietary hardware that required IT teams to manage. The founders saw an opportunity to democratize digital signage - to build something that anyone could set up in minutes, not hours, and that could transform any ordinary screen into a powerful communication tool. Today, OptiSigns powers over 30,000 customers across 120 countries with a cloud-based platform that balances sophistication with simplicity. Headquartered in Houston with a growing engineering presence in Vietnam, the company has expanded from transforming TVs and tablets into dynamic displays to offering interactive kiosks, AI-powered audience analytics, and enterprise-grade platform services. What started as a mission to make digital signage accessible has evolved into a broader vision: helping organizations of all sizes communicate more effectively with their audiences, whether that means boosting retail sales, engaging employees in corporate offices, or enhancing experiences in healthcare facilities. The platform now supports 190,000+ active screens globally, proving that when you remove technical barriers, businesses will find creative ways to connect.

ATU exists to solve the fundamental challenge of automotive maintenance - providing drivers with a reliable, accessible partner for all their vehicle needs. Founded in 1985 in Weiden, Germany, ATU has grown from a single location into Germany's leading automotive service chain with over 500 branches and approximately 10,000 employees across Germany and Austria. The company's unique model combines professional workshops with integrated retail shops, offering customers everything from tires and auto parts to comprehensive vehicle services under one roof. As a Mobivia brand since 2016, ATU continues to transform the automotive aftermarket by combining traditional craftsmanship with modern convenience. The company serves millions of customers annually, providing everything from routine oil changes and inspections to complex repairs, all while maintaining competitive pricing and high quality standards. With both an extensive physical presence and a robust online shop, ATU ensures drivers can access essential automotive services and products wherever and whenever they need them, keeping Germany moving safely and efficiently.

Novasign builds the digital infrastructure for modern bioprocess development. Founded in 2019 as a spin-off from BOKU University in Vienna, the company combines hybrid modeling, machine learning, and digital twin technology to accelerate biopharmaceutical and biotech innovation. The Novasign Studio platform enables scientists and engineers to reduce experimental workload by up to 70% while achieving robust process optimization through intelligent data-driven workflows. The company serves clients across biopharmaceutical manufacturing, enzyme production, and precision fermentation sectors. Novasign's open ecosystem approach integrates seamlessly with third-party solutions, providing collaborative environments where data, models, and knowledge become actionable insights. With a strategic partnership with Repligen and a growing international team, Novasign is redefining how the biotech industry approaches process development and manufacturing optimization.